Abstract
Respiratory syncytial virus (RSV) causes acute respiratory infections, thus, posing a serious threat to the health of infants, children, and elderly people. In this study, we have discovered a series of potent RSV entry inhibitors with the (-)-borneol scaffold. The active compounds 3b, 5a, 5c, 7b, 9c, 10b, 10c, and 14b were found to exhibit activity against RSV A strain A2 in HEp-2 cells. The most active substances, 3b (IC50 = 8.9 μM, SI = 111) and 5a (IC50 = 5.0 μM, SI = 83), displayed more potency than the known antiviral agent Ribavirin (IC50 = 80.0 μM, SI = 50). Time-of-addition assay and temperature shift studies demonstrated that compounds 3b, 5a, and 6b inhibited RSV entry, probably by interacting with the viral F protein that mediated membrane fusion, while they neither bound to G protein nor inhibited RSV attachment to the target cells. Appling procedures of molecular modeling and molecular dynamics, the binding mode of compounds 3b and 5a was proposed. Taken together, the results of this study suggest (-)-borneol esters to be promising lead compounds for developing new anti-RSV agents.
Funder
Russian Science Foundation
Subject
Drug Discovery,Pharmaceutical Science,Molecular Medicine
Reference32 articles.
1. Viruses associated with acute respiratory infection in a community-based cohort of healthy New Zealand children;J. Med. Virol.,2022
2. World Health Organization (2022). COVID-19 Weekly Epidemiological Update, WHO.
3. Influenza Pandemics: Past, Present and Future;J. Formos. Med. Assoc.,2006
4. Bergeron, H.C., and Tripp, R.A. (2021). Immunopathology of RSV: An Updated Review. Viruses, 13.
5. Baraldi, E., Lisi, G.C., Costantino, C., Jon, H., Manzoni, P., Riccò, M., Roberts, M., Baraldi, E., Lisi, G.C., and Costantino, C. (2022). RSV disease in infants and young children: Can we see a brighter future ?. Hum. Vaccin. Immunother., 2079322.